The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

This project will establish a National biobank consortium of Taiwan through the fund support from the government. The National Health Research Institutes will establish a Central Office for the collaboration works, which includes collecting the number of samples of the human biological database in each biobank that agreed to join the Consortium. All Alliance need to follow the same SOP for the collection processthe quality of the biosample. Adequateconsistent clinical data will also be established under the Information Security Management Treaty. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network.In line with the need of biotechnologypharmaceutical industries.

We based on ion trap for mass filter so that ultra-high vacuum is not needed to reduce the weightsize. We took frequency scanning to increase our mass range by 10,000,000,000. We used LED as LC detector to reduce sizecost. Therefore, we not only made a portable device but also a device with many special advantages in technology. An advanced analytical lab can become mobile to easily reach anywhere which needs in-situreal-time analysis by our inventions.

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.

This product provides "Microfluidic sensing system for on-site rapid detection of early-stage acute kidney injury" for the hospital＇s intensive care unit, operating room, nephrology departmentcardiology department. It can replace the lengthycumbersome traditional instrumentationeasily access at the point of care.

Monitoring PCDM-specific biomarkers, galectin-3S100A9, to serve as a risk assessment of pancreatic cancer on new-onset diabetes patients for early detection of PC.

The screening kits were developed using miRNAs for high-risk populations for urothelial carcinoma (UC). Products 702703 are designed for chronic kidney diseasehemodialysis patients using urineblood samples, respectively. With high accuracyminimal invasiveness, the kits are intended to be used as a screeningregular monitoring of UC. If a test reveals a positive result, the patient then undergoes cystoscopic examination for further confirmation. Otherwise, the patent only needs to be monitored annually.

We constructed a model to differentiate different neurodegenerative diseases by using blood-based biomarkers. Linear Discriminant Analysis (LDA) was used to reduce dimensionsMICE (Multivariate Imputation by Chained Equations) was used for missing value treatmentchoose CART model to predict missing value imputation. This machine learning model would be used for early dectection of neurodegenerative diseases.

In the current of study, cell subsets, cell proportionsthe immune function of tumors-infiltrating leukocytes were used to indicate the features of tumor immune microenvironment in non-small cell lung cancers (NSCLCs) with different type of EGFR genetic alteration.

The present technology provides a method for diagnosing Alzheimer＇s disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer＇s disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer＇s disease.